Sebia, Inc.

Sebia, Inc., a for-profit medical diagnostics company headquartered in Norcross, Georgia, manufactures and supplies automated electrophoresis analyzers, reagents, consumables, and clinical laboratory testing services to federal healthcare agencies as a prime contractor, competing full-and-open across its federal portfolio under NAICS 325413 (Laboratory Equipment and Supplies) and PSC 6640 (Laboratory Equipment and Supplies), with no subcontracting activity.

Sebia's federal footprint concentrates heavily in the Department of Veterans Affairs. The top five customer agencies by potential-value share account for 67 percent of combined potential value, led by VA VISN 12 (34 awards, $43.8 million), VA VISN 22 (88 awards, $14.9 million), and VA VISN 8 (61 awards, $13.9 million). The Defense Health Agency (24 awards, $8.2 million) and the Department of the Army Medical Command (49 awards, $6.4 million) round out the dollar concentration. By award count, the rankings shift somewhat: VA VISN 22 places first (88 awards), VA VISN 8 second (61 awards), and VA VISN 23 third (59 awards), accounting for 26 percent of all awards. This customer concentration reflects Sebia's specialized position as the original equipment manufacturer for capillary electrophoresis systems and its established relationships across VA networks.

Sebia's core capability centers on electrophoresis-based diagnostic testing. The company manufactures and supplies Capillarys and Hydrasys systems—proprietary capillary electrophoresis instruments—along with reagents, consumables, installation, training, and maintenance services. Representative work includes a $1,057,761.71 purchase order from the Defense Health Agency (October 2023) for reagents, calibrators, controls, and consumables for Sebia Capillarys 3 Octa analyzers at Madigan Army Medical Center through September 2028; a $505,846.79 single-award indefinite-delivery contract from VA VISN 15 (June 2024) for an Automated Gel Protein Electrophoresis System with a Total Small Business set-aside through June 2029; and a $4,233,230.18 single-award IDIQ from VA VISN 22 (March 2022) for electrophoresis instruments, reagents, supplies, installation, training, and related services at VA medical facilities across California, Arizona, New Mexico, and Nevada through February 2027. Testing capabilities include serum protein electrophoresis, urine protein electrophoresis, hemoglobin A1c analysis, immunofixation testing, and carbohydrate-deficient transferrin analysis.

Sebia holds a dominant position on the Critical Analyzers, Laboratory Federal Supply Schedule (FSS-66-III) with 420 task orders carrying $35 million in combined potential value. Beyond this master vehicle, the company maintains multiple single-award indefinite-delivery contracts and blanket purchase agreements with VA networks. Key IDIQs include the $4.23 million VISN 22 contract (extending through February 2027), the $1.27 million VISN 12 contract (through February 2031), the $3.25 million VISN 8 contract (through September 2030), the $1.4 million VISN 1 BPA (through September 2030), and the $4.47 million Defense Health Agency IDIQ for San Antonio Military Medical Center (through September 2028). The company also holds the $348,430.45 VISN 1 BPA for Lyme testing reagents and supplies (awarded September 2026, through September 2031), which establishes a new geographic and product expansion within the VA network.

Activity has remained relatively flat across the past five years, with 23 awards in 2022, 27 in 2023, 41 in 2024, 36 in 2025, and 19 through October 2026. The combined potential value across all 1,152 prime awards is $130.7 million, with $38.5 million obligated (29 percent). Only 20 awards (combined potential value $3.6 million) face ultimate completion within the next twenty-four months, representing minimal near-term recompete exposure; most awards carry multiyear or indefinite-delivery structures with extended option periods and standing authority to issue task orders through 2028–2031.

Sebia's federal contracting history spans since 1998. The vendor operates exclusively as a prime contractor across its federal footprint with no recorded subcontracting activity. The company does not carry SBA set-aside designations in its prime awards; the vast majority compete full-and-open. Two noted exceptions are a Total Small Business set-aside on the VISN 15 IDIQ (awarded June 2024) and a Total Small Business set-aside delivery order from VISN 17 (awarded December 2021). These represent outliers in an otherwise full-and-open competitive posture. The company's established position as the original equipment manufacturer for its electrophoresis platforms has enabled repeated sole-source and competitive-8(a)-waived awards across VA networks, particularly for Cost-Per-Test and reagent-rental arrangements that leverage existing Phoresis system file compatibility and continuity-of-care justifications.

Sebia's category concentration reflects its focus: In-Vitro Diagnostic Substance Manufacturing accounts for 490 awards, Analytical Laboratory Instrument Manufacturing 171 awards, and Drugs and Druggists' Sundries Merchant Wholesalers 43 awards. PSC-level concentration tracks closely, with Laboratory Equipment and Supplies (PSC 6640) representing 377 awards and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (PSC 4680) accounting for 275 awards. This concentration underscores the vendor's specialization and lack of diversification outside electrophoresis and clinical laboratory diagnostics within the federal market.